A New Preclinical Paradigm for Pancreas Cancer

  • Sunil R. Hingorani


Pancreas cancer confounds patient and physician alike. With an almost identical annual incidence and mortality, the disease has heretofore thwarted attempts to cure and even contain it. The approach to the patient with pancreas cancer is the same as for any cancer: detect it early, diagnose it accurately and eradicate it through a combination of surgery and chemical and radiotherapies. However, cancer of this organ eludes early detection, runs the risk of significant collateral injury when attempting to biopsy it for diagnosis, and resists all current forms of conventional chemotherapy and radiation. Moreover, the disease is as difficult to study in patients as it is to treat. Although classical experimental model systems have yielded significant information on genetic mutations of interest, they have not proved as useful in screening for drugs likely to be effective in patients. Mammalian model systems that faithfully mimic the full spectrum of the human disease from inception to invasion are needed. This chapter describes an integrated translational approach to developing and testing early detection, molecular diagnostic, chemopreventive and therapeutic strategies using state-of-the-art genetically engineered mouse models.


pancreas cancer mouse models translation early detection 


  1. Adsay NV (2005) Pathological classification of cystic neoplasms of the pancreas. In: Von Hoff DD, Evans DB, Hruban RH (eds) Pancreatic Cancer. Jones and Bartlett Publishers, Sudbury, pp 716–756Google Scholar
  2. Aguirre AJ, Bardeesy N, Sinha M et al (2003) Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17:3112–3126CrossRefPubMedGoogle Scholar
  3. Apte MV, Haber PS, Applegate TL et al (1998) Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut 43:128–133CrossRefPubMedGoogle Scholar
  4. Apte MV, Park S, Phillips PA et al (2004) Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 29:179–187CrossRefPubMedGoogle Scholar
  5. Bachem MG, Schneider E, Gross H et al (1998) Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology 115:421–432CrossRefPubMedGoogle Scholar
  6. Bardeesy N, Aguirre AJ, Chu GC et al (2006a) Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 103:5947–5952CrossRefGoogle Scholar
  7. Bardeesy N, Cheng KH, Berger JH et al (2006b) Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 20:3130–3146CrossRefGoogle Scholar
  8. Berlin JD (2007) Adjuvant therapy for pancreatic cancer: to treat or not to treat? Oncology (Williston Park) 21:712–718; discussion 720, 725–716, 730Google Scholar
  9. Bissell MJ, Radisky D (2001) Putting tumours in context. Nat Rev Cancer 1:46–54CrossRefPubMedGoogle Scholar
  10. Burris HA III, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMedGoogle Scholar
  11. Clark CE, Hingorani SR, Mick R et al (2007) Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 67:9518–9527CrossRefPubMedGoogle Scholar
  12. DeVita VT Jr, Chu E (2008) A history of cancer chemotherapy. Cancer Res 68:8643–8653CrossRefPubMedGoogle Scholar
  13. Dickson M, Gagnon JP (2004) Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov 3:417–429CrossRefPubMedGoogle Scholar
  14. Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6:836–848CrossRefPubMedGoogle Scholar
  15. Faca VM, Song KS, Wang H et al (2008) A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 5:e123Google Scholar
  16. Folkman J (1972) Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175:409–416CrossRefPubMedGoogle Scholar
  17. Funahashi H, Satake M, Dawson D et al (2007) Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res 67:7068–7071CrossRefPubMedGoogle Scholar
  18. Grippo PJ, Sandgren EP (2005) Modeling pancreatic cancer in animals to address specific hypotheses. Methods Mol Med 103:217–243PubMedGoogle Scholar
  19. Guerra C, Schuhmacher AJ, Canamero M et al (2007) Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11:291–302CrossRefPubMedGoogle Scholar
  20. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364CrossRefPubMedGoogle Scholar
  21. Heldin CH, Rubin K, Pietras K et al (2004) High interstitial fluid pressure – an obstacle in cancer therapy. Nat Rev Cancer 4:806–813CrossRefPubMedGoogle Scholar
  22. Hermann PC, Huber SL, Herrler T et al (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1:313–323CrossRefPubMedGoogle Scholar
  23. Hertel LW, Boder GB, Kroin JS et al (1990) Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res 50:4417–4422PubMedGoogle Scholar
  24. Hingorani SR (2005) Modeling pancreatic ductal adenocarcinoma in the mouse. In: Gress TM, Neoptolemos JP, Lemoine NR, Real FX (eds) Exocrine pancreas cancer. Felsenstein CCCP Publishing, Hannover, pp 152–171Google Scholar
  25. Hingorani SR (2007) Location, location, location: precursors and prognoses for pancreatic cancer. Gastroenterology 133:345CrossRefPubMedGoogle Scholar
  26. Hingorani SR (2008) From inception to invasion: modeling pathways to pancreatic cancer. In: Lowy AM, Leach SD, Philip PA (eds) Pancreatic Cancer. Springer, US, pp 159–179CrossRefGoogle Scholar
  27. Hingorani SR, Tuveson DA (2003) Targeting oncogene dependence and resistance. Cancer Cell 3:414–417CrossRefPubMedGoogle Scholar
  28. Hingorani SR, Petricoin EF, Maitra A et al (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4:437–450CrossRefPubMedGoogle Scholar
  29. Hingorani SR, Wang L, Multani AS et al (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:469–483CrossRefPubMedGoogle Scholar
  30. Hruban RH (2006) Tumors of the pancreas. In: Hruban RH, Klimstra DS, Pitman MB (eds) Atlas of tumor pathology. Armed Forces Institute of Pathology, Washington, DCGoogle Scholar
  31. Hruban RH, Adsay NV, Albores-Saavedra J et al (2001) Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25:579–586CrossRefPubMedGoogle Scholar
  32. Hruban RH, Takaori K, Klimstra DS et al (2004) An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 28:977–987CrossRefPubMedGoogle Scholar
  33. Hruban RH, Adsay NV, Albores-Saavedra J et al (2006) Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 66:95–106CrossRefPubMedGoogle Scholar
  34. Huxham LA, Kyle AH, Baker JH et al (2004) Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res 64:6537–6541CrossRefPubMedGoogle Scholar
  35. Ijichi H, Chytil A, Gorska AE et al (2006) Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev 20:3147–3160CrossRefPubMedGoogle Scholar
  36. Ikeda N, Adachi M, Taki T et al (1999) Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 79:1553–1563CrossRefPubMedGoogle Scholar
  37. Izeradjene K, Hingorani SR (2007) Targets, trials, and travails in pancreas cancer. J Natl Compr Canc Netw 5:1042–1053PubMedGoogle Scholar
  38. Izeradjene K, Combs C, Best M et al (2007) Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11:229–243CrossRefPubMedGoogle Scholar
  39. Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806CrossRefPubMedGoogle Scholar
  40. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423–436CrossRefPubMedGoogle Scholar
  41. Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz H, McLeod HL, Mulcahy MF, Schilsky RL, Goldberg RM (2007) A double-blind, placebo-controlled randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303 (Abstract). American Society of Clinical Oncology Gastointestinal Cancers Symposium, 19–21. Orlando, FLGoogle Scholar
  42. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–715CrossRefPubMedGoogle Scholar
  43. Lankelma J, Dekker H, Luque FR et al (1999) Doxorubicin gradients in human breast cancer. Clin Cancer Res 5:1703–1707PubMedGoogle Scholar
  44. Leach SD (2004) Mouse models of pancreatic cancer: the fur is finally flying! Cancer Cell 5:7–11CrossRefPubMedGoogle Scholar
  45. Li C, Heidt DG, Dalerba P et al (2007) Identification of pancreatic cancer stem cells. Cancer Res 67:1030–1037CrossRefPubMedGoogle Scholar
  46. Mahadevan D, Von Hoff DD (2007) Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 6:1186–1197CrossRefPubMedGoogle Scholar
  47. Maitra A, Fukushima N, Takaori K et al (2005) Precursors to invasive pancreatic cancer. Adv Anat Pathol 12:81–91CrossRefPubMedGoogle Scholar
  48. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966CrossRefPubMedGoogle Scholar
  49. Mulcahy MF (2007) Adjuvant therapy for pancreas cancer: advances and controversies. Semin Oncol 34:321–326CrossRefPubMedGoogle Scholar
  50. Omary MB, Lugea A, Lowe AW et al (2007) The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Invest 117:50–59CrossRefPubMedGoogle Scholar
  51. Quintana E, Shackleton M, Sabel MS et al (2008) Efficient tumour formation by single human melanoma cells. Nature 456:593–598CrossRefPubMedGoogle Scholar
  52. Radisky D, Hagios C and Bissell MJ (2001) Tumors are unique organs defined by abnormal signaling and context. Semin Cancer Biol 11:87–95CrossRefPubMedGoogle Scholar
  53. Roberts TG Jr, Goulart BH, Squitieri L et al (2004) Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 292:2130–2140CrossRefPubMedGoogle Scholar
  54. Rustgi AK (2006) The molecular pathogenesis of pancreatic cancer: clarifying a complex circuitry. Genes Dev 20:3049–3053CrossRefPubMedGoogle Scholar
  55. Tanaka M, Chari S, Adsay V et al (2006) International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 6:17–32CrossRefPubMedGoogle Scholar
  56. Tannock I (1978) Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep 62:1117–1133PubMedGoogle Scholar
  57. Tuveson DA, Hingorani SR (2005) Ductal pancreatic cancer in humans and mice. Cold Spring Harb Symp Quant Biol 70:65–72CrossRefPubMedGoogle Scholar
  58. Von Hoff DD, Hruban RH, Evans DB (2005) Pancreatic cancer. Jones and Bartlett, Sudbury, MAGoogle Scholar
  59. Walter K, Omura N, Hong SM et al (2008) Pancreatic cancer associated fibroblasts display normal allelotypes. Cancer Biol Ther 7:882–888CrossRefPubMedGoogle Scholar
  60. Waterston RH, Lindblad-Toh K, Birney E et al (2002) Initial sequencing and comparative analysis of the mouse genome. Nature 420:520–562CrossRefPubMedGoogle Scholar
  61. Weinstein IB (2002) Cancer. Addiction to oncogenes–the Achilles heal of cancer. Science 297:63–64CrossRefPubMedGoogle Scholar
  62. Yeh JJ, Der CJ (2007) Targeting signal transduction in pancreatic cancer treatment. Expert Opin Ther Targets 11:673–694CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Clinical Research DivisionFred Hutchinson Cancer Research CenterSeattleUSA

Personalised recommendations